About this trial
The goal of this observational study is to learn what can predict the return of the sense of smell in patients with chronic rhinosinusitis with nasal polyps being treated with dupilumab. The main questions it aims to answer are:
1. Does obstruction of the olfactory cleft predict return of the sense of smell? 2. Do electrophysiological signals generated by breathing and sniffing behavior predict return of the sense of smell?
Participants starting dupilumab will undergo assessment for their degree of olfactory cleft obstruction, and an electrophysiologic assessment of their olfactory cleft and be followed over 6 months of treatment with dupilumab.
Eligibility criteria
Qualifiers
Well documented history of CRSwNP
BSIT age/sex classified as "abnormal" score
Self-reported stable olfactory deficit of moderate to severe quality > 3 months
Prior endoscopic sinus surgery >3 months, <10 years prior
Disqualifiers
None
Trial design
Treatments tested in this trial
- Dupilumab - Standard Dose
Treatment groups
Sponsors and collaborators
Northwestern University
Lead sponsor
Sanofi
Collaborator